NCT02163499 - Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months | Biotech Hunter

Enrollment

751

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Hyperkalemia

Interventions

DRUG

Sodium Zirconium Cyclosilicate

Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.

Trial Locations (50)

2250

Gosford

3050

Parkville

3073

Melbourne

3084

Heidelberg

4102

Woolloongabba

6001

Port Elizabeth

7130

Somerset West

7925

Cape Town

11021

Great Neck

13353

Berlin

29118

Orangeburg

29150

Sumter

31901

Columbus

32168

New Smyrna Beach

32720

DeLand

32789

Winter Park

33015

Miami

33018

Miami Lakes

33125

Miami

33313

Lauderdale Lakes

33511

Brandon

33614

Tampa

34667

Hudson

35768

Scottsboro

37408

Chattanooga

42003

Paducah

48047

Chesterfield

60435

Joliet

60805

Evergreen Park

63110

St Louis

64411

Kansas City

70376

Stuttgart

71101

Shreveport

78215

San Antonio

78229

San Antonio

80230

Denver

84770

St. George

85284

Tempe

85724

Tucson

90022

Los Angeles

90603

Whittier

90717

Chula Vista

90723

Paramount

92505

Riverside

95825

Sacramento

700503

Lasi

02903

Providence

1105 AZ

Amsterdam

Unknown

Meyerspark

LE1 9HN

Leicester

All Listed Sponsors

lead

ZS Pharma, Inc.

INDUSTRY